Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, Dulaglutide is a once-weekly GLP-1RA for type 2 diabetes that lowers HbA1c and body weight by enhancing glucose-dependent insulin secretion and reducing appetite6668.
While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, Dulaglutide is a recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation66.
BPC-157
Not assigned in the current dataset.
Dulaglutide
GCG
BPC-157 and Dulaglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: BPC-157 is more often discussed in the realm of Gastroenterology, Musculoskeletal health, and Dermatology and aesthetics, whereas Dulaglutide is more often associated with the realm of Metabolic and endocrine. Their biological logic is quite different: BPC-157 is a signaling modulator, whereas Dulaglutide is a receptor agonist. BPC-157 has a more synthetic analog origin, while Dulaglutide is closer to engineered peptide background and their development context also differs, with BPC-157 in Preclinical development while Dulaglutide is approved. BPC-157 takes the form of a linear peptide, whereas Dulaglutide is closer to a peptide conjugate, while their sequence patterns also diverge, with BPC-157 showing proline-rich features and Dulaglutide showing alpha-helical domain features.